Reardon Andrew sold $110K of LGND
Reardon Andrew (CLO & Secretary) sold 491 shares of LIGAND PHARMACEUTICALS INC (LGND) at $223.95 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Disclosed insider selling can influence sentiment, but 10b5-1 plans are pre-scheduled and typically carry less informational content than discretionary sales.
Market read
A single disclosed insider sale under a 10b5-1 plan is unlikely to be a standalone catalyst for LGND.
What to watch
The market may still react if the sale is part of a larger pattern of insider reductions, but this article provides only one transaction size and date.
Background
The article is an SEC Form 4 disclosure of an officer/direct insider transaction for Ligand Pharmaceuticals (LGND).
Ticker impact
LGND insider (CLO & Secretary Andrew Reardon) filed an open-market sale of 491 shares under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.
Form 4 insider transactions are typically not material unless unusually large or tied to other company-specific events; here the article provides a modest sale size and confirms a pre-arranged 10b5-1 plan.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide development.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect routine liquidity rather than bearish expectations; traders may discount it entirely.
Key entities
- issuerLGND
Ligand Pharmaceuticals Inc., the subject of the Form 4 insider transaction.
- insiderAndrew Reardon
CLO & Secretary who sold 491 shares on 2026-06-01 under a pre-arranged 10b5-1 plan.
